ResearcherWashington University in St. LouisActive in the last 2 years
Vikas Somani
Matched on ORCID iD 0000-0002-1640-0514; OpenAlex author ID A5074818775. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers
Papers 6
- Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.04.017↗
- Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranostic. Co-author DOI 10.1186/s12943-026-02597-7↗
- Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade Co-author DOI 10.1101/2025.10.08.681226↗
- Chemokine Receptor 2 Targeted PET/CT Imaging Distant Metastases in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1021/acsptsci.3c00303↗
- Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. Co-author DOI 10.1038/s41467-024-46811-w↗
- IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2022.02.035↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- David G DeNardo · 6 shared papers, 2022–2026 · strength 1.21
- Paper Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. DOI 10.1053/j.gastro.2026.04.017↗
- Paper Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade DOI 10.1101/2025.10.08.681226↗
- Paper Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanothe… DOI 10.1186/s12943-026-02597-7↗
- Kian‐Huat Lim · 5 shared papers, 2022–2026 · strength 0.97
- Paper Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. DOI 10.1053/j.gastro.2026.04.017↗
- Paper Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade DOI 10.1101/2025.10.08.681226↗
- Paper Chemokine Receptor 2 Targeted PET/CT Imaging Distant Metastases in Pancreatic Ductal Adenocarcinoma. DOI 10.1021/acsptsci.3c00303↗
- Sapana Bansod · 4 shared papers, 2024–2026 · strength 0.90
- Paper Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. DOI 10.1053/j.gastro.2026.04.017↗
- Paper Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade DOI 10.1101/2025.10.08.681226↗
- Paper Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanothe… DOI 10.1186/s12943-026-02597-7↗
- Ryan C Fields · 3 shared papers, 2024–2026 · strength 0.66
- Paper Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. DOI 10.1053/j.gastro.2026.04.017↗
- Paper Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade DOI 10.1101/2025.10.08.681226↗
- Paper Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. DOI 10.1038/s41467-024-46811-w↗
- Ashenafi Shiferaw Bulle · 3 shared papers, 2024–2026 · strength 0.65
- Paper Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. DOI 10.1053/j.gastro.2026.04.017↗
- Paper Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanothe… DOI 10.1186/s12943-026-02597-7↗
- Paper Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. DOI 10.1038/s41467-024-46811-w↗
- Liang‐I Kang · 3 shared papers, 2022–2026 · strength 0.55
- Paper Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanothe… DOI 10.1186/s12943-026-02597-7↗
- Paper Chemokine Receptor 2 Targeted PET/CT Imaging Distant Metastases in Pancreatic Ductal Adenocarcinoma. DOI 10.1021/acsptsci.3c00303↗
- Paper IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1053/j.gastro.2022.02.035↗
- Patrick M. Grierson · 2 shared papers, 2022–2024 · strength 0.29
- Paarth B. Dodhiawala · 2 shared papers, 2022–2024 · strength 0.29
- Kian-Huat Lim · 1 shared paper, 2026 · strength 0.24
- Yongjian Liu · 1 shared paper, 2024 · strength 0.17
- Farrokh Dehdashti · 1 shared paper, 2024 · strength 0.17
- Xiaohui Zhang · 1 shared paper, 2024 · strength 0.17
- William G. Hawkins · 1 shared paper, 2024 · strength 0.15
- Ramaswamy Govindan Md · 1 shared paper, 2024 · strength 0.15
- Li Ding · 1 shared paper, 2024 · strength 0.15
- Andrea Wang‐Gillam · 1 shared paper, 2024 · strength 0.15
- Varintra E. Lander · 1 shared paper, 2022 · strength 0.14
- Daoxiang Zhang · 1 shared paper, 2022 · strength 0.14
- Lin Li · 1 shared paper, 2022 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.